WST West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.
Company profile
Ticker
WST
Exchange
CEO
Eric Mark Green
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Former names
West Co Inc
SEC CIK
Corporate docs
IRS number
231210010
WST stock data
()
Calendar
29 Jul 19
21 Oct 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 469.7M | 443.5M | 422.5M | 431.7M | |
| Diluted EPS | 0.88 | 0.73 | 0.69 | 0.73 | |
| Operating income | 80.5M | 70.7M | 65.8M | 60.8M | |
| Net change in cash | 61.2M | -71.9M | 40.1M | 71.8M | |
| Cash on hand | 326.7M | 265.5M | 337.4M | 297.3M | |
| Cost of revenue | 311.8M | 296.7M | 289.3M | 296.1M |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 1.72B | 1.6B | 1.51B | 1.4B | |
| Diluted EPS | 2.74 | 1.99 | 1.91 | 1.3 | |
| Operating income | 240.3M | 225.8M | 195.2M | 128.6M | |
| Net change in cash | 101.5M | 32.9M | -71.6M | 19.3M | |
| Cash on hand | 337.4M | 235.9M | 203M | 274.6M | |
| Cost of revenue | 1.17B | 1.09B | 1.01B | 944M |
Financial data from company earnings reports
Financial report summary
?Management Discussion
- We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Good
|
|
New words:
CZ, fourth, goodwill, intangible, Korean, original, recent, Won
Removed:
calculated, capitalized, charge, translating
Financial reports
10-Q
2019 Q2
Quarterly report
29 Jul 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
30 Oct 18
10-Q
2018 Q2
Quarterly report
31 Jul 18
10-Q
2018 Q1
Quarterly report
8 May 18
10-K
2017 FY
Annual report
26 Feb 18
10-Q
2017 Q3
Quarterly report
31 Oct 17
10-Q
2017 Q2
Quarterly report
1 Aug 17
10-Q
2017 Q1
Quarterly report
5 May 17
Current reports
8-K
Longstanding Partnership in Injectable Drug Delivery
16 Oct 19
8-K
Departure of Directors or Certain Officers
2 Oct 19
8-K
West Pharmaceutical Services, Inc. September 2019 Investor Presentation
4 Sep 19
8-K
Announces an Increase to Fourth-Quarter 2019 Dividend
25 Jul 19
8-K
West Pharmaceutical Services, Inc. Spring 2019 Investor Presentation
14 May 19
8-K
West Announces First-Quarter 2019 Results
25 Apr 19
8-K
Entry into a Material Definitive Agreement
1 Apr 19
8-K
Departure of Directors or Certain Officers
27 Feb 19
8-K
West Announces Quarterly Dividend and Share Repurchase Program
21 Feb 19
8-K
West Announces Fourth-Quarter and Full-Year 2018 Results
14 Feb 19
Registration and prospectus
S-8
Registration of securities for employees
3 May 16
SC TO-C
Information about tender offer
8 May 12
S-8
Registration of securities for employees
12 May 11
S-8
Registration of securities for employees
29 Dec 10
S-8
Registration of securities for employees
30 Dec 08
424B7
Prospectus with selling stockholder info
28 Feb 08
S-3ASR
Automatic shelf registration
7 Aug 07
S-8
Registration of securities for employees
1 Jun 07
S-8
Registration of securities for employees
21 May 07
424B5
Prospectus supplement for primary offering
12 Mar 07
Proxies
DEFA14A
Additional proxy soliciting materials
22 Mar 19
DEF 14A
Definitive proxy
22 Mar 19
DEF 14A
Definitive proxy
21 Mar 18
DEFA14A
Additional proxy soliciting materials
21 Mar 18
DEFA14A
Additional proxy soliciting materials
14 Apr 17
DEF 14A
Definitive proxy
22 Mar 17
DEFA14A
Additional proxy soliciting materials
16 Mar 17
DEFA14A
Additional proxy soliciting materials
24 Mar 16
DEF 14A
Definitive proxy
23 Mar 16
DEFA14A
Additional proxy soliciting materials
23 Mar 16
Other
SD
Conflict minerals disclosure
30 May 19
CT ORDER
Confidential treatment order
21 Aug 18
SD
Conflict minerals disclosure
25 May 18
SD
Conflict minerals disclosure
26 May 17
CT ORDER
Confidential treatment order
17 Mar 17
CT ORDER
Confidential treatment order
6 Dec 16
CT ORDER
Confidential treatment order
15 Sep 16
SD
Conflict minerals disclosure
27 May 16
SD
Conflict minerals disclosure
1 Jun 15
CT ORDER
Confidential treatment order
9 Oct 14